Captopril-d3 – 250 µg

Brand:
Cayman
CAS:
1356383-38-4
Storage:
-20
UN-No:
Non-Hazardous - /

Captopril-d3 is intended for use as an internal standard for the quantification of captopril (Item No. 15313) by GC- or LC-MS. Captopril is a first generation nonpeptidic ACE inhibitor (IC50 = 6.3 nM) that was designed based on bradykinin-potentiating peptides isolated from the venom of B. jararaca, a pit viper native to Brazil. {25198,25199,25197} It does not exhibit a domain preference for binding either the C- or N-terminal active sites of the somatic form of ACE.{25198} Acute and chronic administration of captopril reduces blood pressure in spontaneously hypertensive Wistar-Kyoto rats and does not induce hypotension in salt-repleted normotensive Wistar-Kyoto rats.{42208} Captopril is also a competitive and reversible inhibitor of leukotriene (LTA4) hydrolase, which results in the disruption of LTB4 synthesis with an IC50 value of 14 μM.{25196}  

 

Available on backorder

SKU: 25235 - 250 µg Category:

Description

An internal standard for the quantification of captopril by GC- or LC-MS


Formal name: (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic-2,5,5-d3 acid

Synonyms: 

Molecular weight: 220.3

CAS: 1356383-38-4

Purity: ≥99% deuterated forms (d1-d3)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|Angiotensin-converting Enzyme||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension